{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T07:12:27Z","timestamp":1779261147616,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,19]]},"DOI":"10.7759\/cureus.109243","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:27:21Z","timestamp":1779258441000},"source":"Crossref","is-referenced-by-count":0,"title":["Is Early Injection-Site Reaction Associated With the Efficacy of Romosozumab?"],"prefix":"10.7759","author":[{"given":"Takaomi","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Kobayakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadatsugu","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-025-01590-2","article-title":"Sequential and combination therapy with romosozumab","volume":"43","author":"Kobayakawa T","year":"2025","unstructured":"Kobayakawa T. Sequential and combination therapy with romosozumab. J Bone Miner Metab. 2025, 43:10-7. 10.1007\/s00774-025-01590-2","journal-title":"J Bone Miner Metab"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-024-01531-5","article-title":"Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials","volume":"42","author":"Kobayashi T","year":"2024","unstructured":"Kobayashi T, Hara M, Shimanoe C, Morimoto T, Masaaki M, Ito K, Shimazaki T. Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials. J Bone Miner Metab. 2024, 42:492-502. 10.1007\/s00774-024-01531-5","journal-title":"J Bone Miner Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2017.07.005","article-title":"Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study","volume":"103","author":"Ishibashi H","year":"2017","unstructured":"Ishibashi H, Crittenden DB, Miyauchi A, et al.. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone. 2017, 103:209-15. 10.1016\/j.bone.2017.07.005","journal-title":"Bone"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2020.848","article-title":"Romosozumab in postmenopausal Korean women with osteoporosis: a randomized, double-blind, placebo-controlled efficacy and safety study","volume":"36","author":"Baek KH","year":"2021","unstructured":"Baek KH, Chung YS, Koh JM, et al.. Romosozumab in postmenopausal Korean women with osteoporosis: a randomized, double-blind, placebo-controlled efficacy and safety study. Endocrinol Metab (Seoul). 2021, 36:60-9. 10.3803\/EnM.2020.848","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman F","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, et al.. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016, 375:1532-43. 10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung MR","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, et al.. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014, 370:412-20. 10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116480","article-title":"Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study","volume":"162","author":"Kobayakawa T","year":"2022","unstructured":"Kobayakawa T, Miyazaki A, Takahashi J, Nakamura Y. Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study. Bone. 2022, 162:116480. 10.1016\/j.bone.2022.116480","journal-title":"Bone"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91248-6","article-title":"Denosumab versus romosozumab for postmenopausal osteoporosis treatment","volume":"11","author":"Kobayakawa T","year":"2021","unstructured":"Kobayakawa T, Miyazaki A, Saito M, Suzuki T, Takahashi J, Nakamura Y. Denosumab versus romosozumab for postmenopausal osteoporosis treatment. Sci Rep. 2021, 11:11801. 10.1038\/s41598-021-91248-6","journal-title":"Sci Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2022.02.002","article-title":"Effects of romosozumab with and without active vitamin D analog supplementation for postmenopausal osteoporosis","volume":"48","author":"Kobayakawa T","year":"2022","unstructured":"Kobayakawa T, Miyazaki A, Takahashi J, Nakamura Y. Effects of romosozumab with and without active vitamin D analog supplementation for postmenopausal osteoporosis. Clin Nutr ESPEN. 2022, 48:267-74. 10.1016\/j.clnesp.2022.02.002","journal-title":"Clin Nutr ESPEN"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-024-01570-y","article-title":"Responders and non-responders to romosozumab treatment","volume":"43","author":"Tominaga A","year":"2025","unstructured":"Tominaga A, Wada K, Kato Y, Okazaki K. Responders and non-responders to romosozumab treatment. J Bone Miner Metab. 2025, 43:18-21. 10.1007\/s00774-024-01570-y","journal-title":"J Bone Miner Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-023-01087-y","article-title":"Nonresponder considerations for romosozumab treatment","volume":"113","author":"Tominaga A","year":"2023","unstructured":"Tominaga A, Wada K, Okazaki K, et al.. Nonresponder considerations for romosozumab treatment. Calcif Tissue Int. 2023, 113:157-65. 10.1007\/s00223-023-01087-y","journal-title":"Calcif Tissue Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06642-1","article-title":"Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis","volume":"34","author":"Kashii M","year":"2023","unstructured":"Kashii M, Kamatani T, Nagayama Y, Miyama A, Tsuboi H, Ebina K. Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis. Osteoporos Int. 2023, 34:563-72. 10.1007\/s00198-022-06642-1","journal-title":"Osteoporos Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roae008","article-title":"Association between P1NP value and increases in bone mineral density in patients with postmenopausal osteoporosis treated with romosozumab","volume":"34","author":"Hattori K","year":"2024","unstructured":"Hattori K, Kanayama Y. Association between P1NP value and increases in bone mineral density in patients with postmenopausal osteoporosis treated with romosozumab. Mod Rheumatol. 2024, 34:1047-55. 10.1093\/mr\/roae008","journal-title":"Mod Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2023.0535","article-title":"Predictive factors for increased bone density following romosozumab administration based on pre-administration blood test results","volume":"66","author":"Kuwabara A","year":"2025","unstructured":"Kuwabara A, Inage K, Yamashita M, et al.. Predictive factors for increased bone density following romosozumab administration based on pre-administration blood test results. Yonsei Med J. 2025, 66:226-32. 10.3349\/ymj.2023.0535","journal-title":"Yonsei Med J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117164","article-title":"Real-world effects, safety, and predictors of the effectiveness of romosozumab in primary and secondary osteoporosis: An observational study","volume":"186","author":"Mineta K","year":"2024","unstructured":"Mineta K, Nishisho T, Okada M, Kamada M, Sairyo K. Real-world effects, safety, and predictors of the effectiveness of romosozumab in primary and secondary osteoporosis: An observational study. Bone. 2024, 186:117164. 10.1016\/j.bone.2024.117164","journal-title":"Bone"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115574","article-title":"Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis","volume":"140","author":"Ebina K","year":"2020","unstructured":"Ebina K, Hirao M, Tsuboi H, et al.. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone. 2020, 140:115574. 10.1016\/j.bone.2020.115574","journal-title":"Bone"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07155-9","article-title":"The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland","volume":"35","author":"Everts-Graber J","year":"2024","unstructured":"Everts-Graber J, Wenger M, Oser S, et al.. The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland. Osteoporos Int. 2024, 35:1605-13. 10.1007\/s00198-024-07155-9","journal-title":"Osteoporos Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101068","article-title":"Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study","volume":"14","author":"Kobayakawa T","year":"2021","unstructured":"Kobayakawa T, Suzuki T, Nakano M, Saito M, Miyazaki A, Takahashi J, Nakamura Y. Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study. Bone Rep. 2021, 14:101068. 10.1016\/j.bonr.2021.101068","journal-title":"Bone Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-020-00563-w","article-title":"The effects of sclerostin on the immune system","volume":"18","author":"Donham C","year":"2020","unstructured":"Donham C, Manilay JO. The effects of sclerostin on the immune system. Curr Osteoporos Rep. 2020, 18:32-7. 10.1007\/s11914-020-00563-w","journal-title":"Curr Osteoporos Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179111","article-title":"Sclerostin depletion induces inflammation in the bone marrow of mice","volume":"22","author":"Donham C","year":"2021","unstructured":"Donham C, Chicana B, Robling AG, et al.. Sclerostin depletion induces inflammation in the bone marrow of mice. Int J Mol Sci. 2021, 22:10.3390\/ijms22179111","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)00004-2","article-title":"Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism","volume":"13","author":"Reya T","year":"2000","unstructured":"Reya T, O'Riordan M, Okamura R, Devaney E, Willert K, Nusse R, Grosschedl R. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity. 2000, 13:15-24. 10.1016\/s1074-7613(00)00004-2","journal-title":"Immunity"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2334","article-title":"Frizzled 9 knock-out mice have abnormal B-cell development","volume":"105","author":"Ranheim EA","year":"2005","unstructured":"Ranheim EA, Kwan HC, Reya T, Wang YK, Weissman IL, Francke U. Frizzled 9 knock-out mice have abnormal B-cell development. Blood. 2005, 105:2487-94. 10.1182\/blood-2004-06-2334","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.11005\/jbm.2016.23.1.16","article-title":"Serum sclerostin levels in patients with human immunodeficiency virus infection and their association with bone turnover markers and bone mineral densitometry","volume":"23","author":"Almansouri AY","year":"2016","unstructured":"Almansouri AY, Abdulfatah ME, Baaqil OH, et al.. Serum sclerostin levels in patients with human immunodeficiency virus infection and their association with bone turnover markers and bone mineral densitometry. J Bone Metab. 2016, 23:16-22. 10.11005\/jbm.2016.23.1.16","journal-title":"J Bone Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-7-13","article-title":"Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis","volume":"7","author":"D\u00f8sen G","year":"2006","unstructured":"D\u00f8sen G, Tenstad E, Nygren MK, Stubberud H, Funderud S, Rian E. Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis. BMC Immunol. 2006, 7:13. 10.1186\/1471-2172-7-13","journal-title":"BMC Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-021-01091-3","article-title":"Increased circulating sclerostin levels in rheumatoid arthritis patients: an updated meta-analysis","volume":"82","author":"Mao YM","year":"2023","unstructured":"Mao YM, Liao T, Ye QL, et al.. Increased circulating sclerostin levels in rheumatoid arthritis patients: an updated meta-analysis. Z Rheumatol. 2023, 82:51-8. 10.1007\/s00393-021-01091-3","journal-title":"Z Rheumatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.602330","article-title":"The roles of sclerostin in immune system and the applications of aptamers in immune-related research","volume":"12","author":"Sun M","year":"2021","unstructured":"Sun M, Chen Z, Wu X, et al.. The roles of sclerostin in immune system and the applications of aptamers in immune-related research. Front Immunol. 2021, 12:602330. 10.3389\/fimmu.2021.602330","journal-title":"Front Immunol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00058","article-title":"Osteoimmunology: a current update of the interplay between bone and the immune system","volume":"11","author":"Guder C","year":"2020","unstructured":"Guder C, Gravius S, Burger C, Wirtz DC, Schildberg FA. Osteoimmunology: a current update of the interplay between bone and the immune system. Front Immunol. 2020, 11:58. 10.3389\/fimmu.2020.00058","journal-title":"Front Immunol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-021-01484-9","article-title":"The pathophysiology of immunoporosis: innovative therapeutic targets","volume":"70","author":"Ferbebouh M","year":"2021","unstructured":"Ferbebouh M, Valli\u00e8res F, Benderdour M, Fernandes J. The pathophysiology of immunoporosis: innovative therapeutic targets. Inflamm Res. 2021, 70:859-75. 10.1007\/s00011-021-01484-9","journal-title":"Inflamm Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-013-0447-8","article-title":"Diagnostic criteria for primary osteoporosis: year 2012 revision","volume":"31","author":"Soen S","year":"2013","unstructured":"Soen S, Fukunaga M, Sugimoto T, et al.. Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab. 2013, 31:247-57. 10.1007\/s00774-013-0447-8","journal-title":"J Bone Miner Metab"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1891002","article-title":"Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response","volume":"10","author":"Zhuang CL","year":"2021","unstructured":"Zhuang CL, Lin ZJ, Bi ZF, et al.. Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response. Emerg Microbes Infect. 2021, 10:365-75. 10.1080\/22221751.2021.1891002","journal-title":"Emerg Microbes Infect"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/476835-is-early-injection-site-reaction-associated-with-the-efficacy-of-romosozumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:27:22Z","timestamp":1779258442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/476835-is-early-injection-site-reaction-associated-with-the-efficacy-of-romosozumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.109243","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,19]]}}}